GMT Capital’s Integra LifeSciences IART Stock Holding History

GMT Capital’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,000,000	Closed	-$1.95M	–	69
2024 Q3	$1.95M	Buy	+2,000,000	New	+$46.4M	0.08%	47

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GMT Capital's IART Position: Q4 2024 in Review

GMT Capital sold out of Integra LifeSciences (IART) in Q4 2024, closing a stake of 2,000,000 shares — an estimated $1.95M sold.

GMT Capital first reported a position in IART in Q3 2024 and held it in 1 quarter. The position peaked at $1.95M in Q3 2024. 223 funds tracked by Wall St. Rank hold IART as of Q4 2024.

GMT Capital reported no remaining Integra LifeSciences position as of Q4 2024 after selling out during the quarter.
GMT Capital sold 2,000,000 Integra LifeSciences shares in Q4 2024, an estimated $1.95M.
GMT Capital first reported a position in Integra LifeSciences in Q3 2024 and held it in 1 quarter.
GMT Capital's Integra LifeSciences position peaked at $1.95M in Q3 2024.
223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2024.

Based on GMT Capital's 13F filing for Q4 2024, filed 14 Feb 2025.